Talking to patients about Lenacapavir (Sunlenca); the new long-acting injectable medication for HIV Conversations with CEI

In this episode, Dr. Steven Fine, an infectious disease specialist affiliated with the University ofRochester and Anthony Jordan Health Center explains the pros and cons behind the newlyapproved Lenacapavir (Sunlenca) injectable for HIV.Dr. Fine receives a lot of questions about the medication in his practice. Many patients haveheard good things about the new treatment for HIV that is given as a subcutaneous injectiononce every 6 months. Dr. Fine discusses the current indication in combination with other agentsfor “treatment-experienced” HIV patients and possible future uses. You’ll hear aboutLenacapavir, the data that led to approval, and how it may be used in the future - includingpossibly for Pre-Exposure Prophylaxis (PrEP).
Related Content:
The Capella Trial for Lenocapavir
CROI 2023
FDA Approves New HIV Drug for Adults with Limited Treatment Options
CEI toll free line for NYS providers: 866-637-2342
Visit us at https://ceitraining.org/